carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - mnohočetný myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
aspaveli
swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinurie, paroxysmální - imunosupresiva - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastická činidla - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastická činidla - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
trumenba
pfizer europe ma eeig - neisseria meningitidis séroskupina b fhbp (rekombinantní lipidovaná fhbp (vazebný protein faktoru h)) podrodina a; neisseria meningitidis séroskupina b fhbp (rekombinantní lipidovaná fhbp (faktor h vazebný protein)) podrodina b - meningitida, meningokoková - bacterial vaccines, meningococcal vaccines - trumenba je indikován k aktivní imunizaci jedinců 10 let k prevenci invazivní meningokokové onemocnění způsobené neisseria meningitidis séroskupiny b. použití této vakcíny musí být v souladu s oficiálními doporučeními.
bexsero
gsk vaccines s.r.l. - vnější membrána váčků z neisseria meningitidis skupiny b (kmen nz 98/254), rekombinantní bakterií neisseria meningitidis skupiny b fúzní protein fhbp, rekombinantní bakterií neisseria meningitidis skupiny b nada proteinů, rekombinantní bakterií neisseria meningitidis skupiny b fúzní protein nhba - meningitida, meningokoková - meningokokové vakcíny - aktivní imunizace proti invazivním onemocněním vyvolaným kmeny neisseria meningitidis serogroup-b.
menveo
gsk vaccines s.r.l. - meningokoková skupina a, c, w-135 a y konjugovaná vakcína - immunization; meningitis, meningococcal - bakteriální vakcíny - vialsmenveo je indikována pro aktivní imunizaci dětí (od dvou let věku), dospívajících a dospělých s rizikem expozice neisseria meningitidis skupin a, c, w135 a y, k prevenci invazivních onemocnění. použití této vakcíny musí být v souladu s oficiálními doporučeními.
lunsumio
roche registration gmbh - mosunetuzumab - lymfom, folikulární - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastická činidla - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
talvey
janssen-cilag international n.v. - talquetamab - mnohočetný myelom - antineoplastická činidla - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.